Summary
Transdermal delivery of dopamine agonists (DA) is a promising therapeutic concept, which aims to ameliorate frequency and intensity of motor fluctuations in patients with Parkinson’s disease (PD). We treated 8 PD patients with unpredictable on-off phenomena with lisuride patches (release: 2–5/μg lisuride base/cm2/hour in mice) in addition to their preexisting antiparkinsonian drug regime up to a period of 8 days. In order to quantify the intensity and frequency of motor fluctuations, we determined the motor changing rate (MCR), which corresponds to the patient’s self rating of motor function, performed every thirty minutes, divided through the number of scored intervals minus 1. Additional lisuride patch application significantly (p = 0.023) improved the MCR compared to baseline. Relevant side effects were transient skin irritations in four patients. Our observational study demonstrates the safety, tolerability and efficacy of transdermal lisuride delivery in the treatment of motor complications.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Baas H, Harder S, Demisch L, Burklin F, Stecker K, Fischer PA (1995) Fluctuations in Parkinson’s disease. Pathogenetic significance of levodopa’s cerebral pharmacokinetics and pharmacodynamics. J Neural Transm [Suppl] 46: 367–379
Behrens S, Sommerville K (2003) Non-oral drug delivery in Parkinson’s disease: a summary from the symposium at the 7th International Congress of Parkinson’s Disease and Movement Disorders, 10-14 November 2002, Miami, FL, USA. Expert Opin Pharmacother 4: 595–599
Danhof M, van der Geest R, van Laar T, Bodde HE (1998) An integrated pharmacokinetic-pharmacodynamic approach to optimization of R-apomorphine delivery in Parkinson’s disease. Adv Drug Delivery Rev 33: 253–263
Deleu D, Northway MG, Hanssens Y (2002) Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson’s disease. Clin Pharmacokinet 41: 261–309
Hoehn MM, Yahr MD (2001) Parkinsonism: onset, progression, and mortality. 1967. Neurology 57: S11–S26
Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinic al diagnosis of idiopathic Parkinson’ s disease: a clinico-pathological study of 100 case s [see comments]. J Neurol Neurosurg Psychiatry 55: 181–184
Metman LV, Gillespie M, Fanner C, Bibbiani F, Konitsiotis S, Morris M, Shill H, Bara-Jimenez W Mouradian MM, Chase TN (2001) Continuous transdennal dopaminergic stimulation in advanced Parkinson’s disease. Clin Neurophannacol 24: 163–169
Montastruc JL, Ziegler M, Rascol O, Malbezin M (1999) A randomized, double-blind study of a skin patch of a dopaminergic agonist, piribedil, in Parkinson’s disease. Mov Disord 14: 336–341
Müller T (2002) Dopaminergic substitution in Parkinson’s disease. Expert Opin Phannacother 3: 1393–1403
Pfeiffer RF (2002) Potential oftransdennal drug delivery in Parkinson’s disease. Drugs & Aging 19: 561–570
Poewe WH, Deuschl G, Gordin A, Kultalahti ER, Leinonen M (2002 ) Efficacy and safety of entacapone in Parkinson’s disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). Acta Neurol Scand 105: 245–255
Rinne UK (1999 ) [Combination therapy with lisuride and L-dopa in the early stages of Parkin son’s disease decreases and delays the development of motor fluctuation s. Long-term study over 10 years in comparison with L-dopa monotherapy]. Nervenarzt 70[Suppl 1]: S19–S25
Sudo J, Iwase H, Terui J, Kakuno K, Soyama M, Takayama K, Nagai T (1998 ) Transdennal absorption of L-dopa from hydrogel in rats. Eur J Pharmaceut Sci 7: 67–71
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Springer-Verlag Wien
About this chapter
Cite this chapter
Woitalla, D., Müller, T., Benz, S., Horowski, R., Przuntek, H. (2004). Transdermal lisuride delivery in the treatment of Parkinson’s disease. In: Müller, T., Riederer, P. (eds) Focus on Extrapyramidal Dysfunction. Journal of Neural Transmission. Supplementa, vol 68. Springer, Vienna. https://doi.org/10.1007/978-3-7091-0579-5_10
Download citation
DOI: https://doi.org/10.1007/978-3-7091-0579-5_10
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-21114-4
Online ISBN: 978-3-7091-0579-5
eBook Packages: Springer Book Archive